tbuckley/cabot-search huggingface dataset:
AB0313 Correlation of the Novel Multi-Biomarker Disease Activity Assay (MBDA, VECTRA-DA) and its Components with the Traditional Serologic Markers of Inflammation ESR and CRP in a Real Life Clinical Setting: Table 1.
Authors: S. Chittalae, O. Shuaib, H. Hakeem, S. Kadavath, M. Briggs, P. Efthimiou
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> The rheumatoid arthritis is one of the most severe and widespread systemic inflammatory autoimmune diseases. The biomarkers play an important role in early diagnostics, activity evaluation, severity of disease course, disease prognosis and effectiveness of applied therapy. Traditional inflammatory biomarkers such as ESR (erythrocyte sedimentation rate) and CRP (c-reactive protein) can be in the normal range in approximately 40% of RA patients. MBDA has been proposed as an objective measure of disease activity for patients with RA. MBDA is a cumulative score based on the serum concentrations of 12 serum proteins (biomarkers); the score has been validated for use in RA. MBDA can provide a baseline assessment of RA disease activity and track it over time. But Interpretation of individual biomarker results has not been validated. <h3>Objectives</h3> To compare the MBDA (VECTRA-DA) scores with traditional serologic markers of inflammation (ESR, CRP), as well as the relative contribution of the individual cytokines comprising the MBDA, for the assessment of RA activity in a real life clinical practice setting. <h3>Methods</h3> A retrospective chart review study was conducted in an urban teaching hospital and 150 patients with RA were identified, fulfilling the 2010 ACR diagnostic criteria. The study was approved by the ethics committee, and simultaneous blood draws were performed for Vectra-DA, ESR and CRP during routine clinic visits over a period of one year. We compared the VECTRA test results in Rheumatoid Arthritis patients with ESR and CRP (Table 1) and analyzed the contribution of the individual components of the MBDA toward its composite score. <h3>Results</h3> see Table 1. <h3>Conclusions</h3> The novel MBDA test VECTRA-DA provides additional information, beyond the traditional serologic markers of inflammation ESR and CRP, toward the assessment of RA disease activity. VCAM, TNF-RI and IL-6 levels appear to have a major influence on the composite MBDA score that is associated with disease activity. <h3>Disclosure of Interest</h3> S. Chittalae: None declared, O. Shuaib: None declared, H. Hakeem: None declared, S. Kadavath: None declared, M. Briggs: None declared, P. Efthimiou Consultant for: crescendo bioscience
Screening for Thyroid Disease: Recommendation Statement
Journal: Annals of Internal Medicine (2004)

This statement summarizes the current U.S. Preventive Services Task Force (USPSTF) recommendations on screening for thyroid disease and updates the 1996 recommendations on this topic. The complete USPSTF recommendation statement on this topic, which includes a brief review of the supporting evidence, is available through the USPSTF Web site (www.preventiveservices.ahrq.gov), the National Guideline Clearinghouse (www.guideline.gov), and in print through the Agency for Healthcare Research and Quality Publications Clearinghouse (telephone, 800-358-9295; e-mail, ahrqpubs.gov). The complete information on which this statement is based, including evidence tables and references, is available in the accompanying article in this issue and in the summary of the evidence and systematic evidence review on the Web sites already mentioned. The recommendation statement and article are also available in print through the Agency for Healthcare Research and Quality Publications Clearinghouse. *For a list of the members of the U.S. Preventive Services Task Force, see the Appendix.
6-Sulphatoxy melatonin in melancholia
Authors: P M Boyce
Journal: American Journal of Psychiatry (1985)

The daytime and nighttime levels of 6-sulphatoxy melatonin, a metabolite of melatonin, were measured in eight melancholic patients. Three patients did not show a marked nocturnal increase in 6-sulphatoxy melatonin excretion. The author discusses the relationship between melatonin and melancholia.
Administration of interleukin-7 increases CD4 T cells in idiopathic CD4 lymphocytopenia
Authors: Virginia Sheikh, Brian O. Porter, Rebecca DerSimonian, Stephen B. Kovacs, William L. Thompson, Ainhoa Perez-Diez, Alexandra F. Freeman, Gregg Roby, JoAnn Mican, Alice Pau, Adam Rupert, Joseph Adelsberger, Jeanette Higgins, Jeffrey S. Bourgeois, Stig M. R. Jensen, David R. Morcock, Peter D. Burbelo, Leah Osnos, Irina Maric, Ven Natarajan, Therese Croughs, Michael D. Yao, Jacob D. Estes, Irini Sereti
Journal: Blood (2015)
Increased sympathetic nervous system activity in alcoholic patients treated with disulfiram
Authors: C R Lake, L F Major, M G Ziegler, I J Kopin
Journal: American Journal of Psychiatry (1977)

The authors measured plasma levels of norepinephrine (NE) and dopamine beta-hydroxylase (DBH), pulse rates, and blood pressures of 81 hospitalized alcoholic patients. Treatment with 500 mg/day of disulfiram (but not 250 mg/day or placebo) resulted in small but significant increases in plasma NE and in blood pressure. The 500-mg dose did not appreciably inhibit DBH. Patients receiving high doses of disulfiram should have their blood pressure monitored and their dose decreased to 250 mg/day when possible.
Irradiated blood products to prevent graft-versus-host disease.
Authors: A B Whiteley
Journal: Journal of Clinical Oncology (1992)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1992.10.3.506 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 1740686 Irradiated blood products to prevent graft-versus-host disease. A B WhiteleyxA B WhiteleySearch for articles by this author https://doi.org/10.1200/JCO.1992.10.3.506 PDF "Irradiated blood products to prevent graft-versus-host disease.." Journal of Clinical Oncology, 10(3), p. 506© 1992 by American Society of Clinical Oncology
From the Editor
Authors: Susan E. Bates
Journal: Clinical Cancer Research (2008)

For many oncologists, a biostatistician's work can be easily characterized as anenigma. We know that all clinical trial or laboratory data must be framed instatistical language and have deep respect for someone who knows whichtest to apply when. This issue of CCR Focus is aimed at bridging the gapbetween biostatistician and oncologist in our world of targeted therapy andgenomic analyses.Over the past decade, the biostatistician's work in oncology has steadilyexpanded as we ask not only which clinical trial results are valid, but also whatsets of genes among thousands evaluated are relevant to the clinical question. Asone example, among the increasing numbers of gene signatures evaluatingbreast cancer prognosis derived from cDNA microarray work, there appears tobe some prognostic concordance but with little overlap in gene identity(Haibe-Kains B, et al. BMC Genomics 9:394, 2008). With an Affymetrix chipcontaining over 20,000 genes, at P = 0.05, 1000 genes will reach statisticalsignificance by random chance for high expression in breast cancer samples ifno additional filters are applied. This simple concept may explain the lack ofoverlap. How, then, can investigators determine which signature, or whichbiomarker has been appropriately validated, and how can that signature orbiomarker be used in translational clinical trials?The articles in this issue of CCR Focus, contributed by experts in the field,address several facets of this problem, beginning with an overview byStephen L. George as Guest Editor that highlights the contributions that follow.Chau, MacLeod, and Figg discuss validation of analytic methods for biomarkersused in drug development. Owzar et al. evaluate the necessary preprocessing ofmicroarray data - those early steps in microarray analysis that have major impacton final outcome. Taylor, Ankerst, and Andridge consider validation ofprediction models using genomic analyses. Finally, both George in the Focusoverview and Simon explore methods of clinical trial design that incorporatebiomarker detection. As with every issue of CCR Focus, our goal is that thesearticles will inform the clinical cancer researcher who is interested but notexpert in the field, but also stimulate the thinking of the expert. In the case ofthis CCR Focus on Biostatistics and Biomarkers, it is hoped that these articles fortranslational cancer researchers can begin to unravel the enigma.
Initial management of the severely injuried patient
Authors: G. T. Shires
Journal: JAMA (1970)

Immediate categorization and an organized plan of management serve to expedite and improve medical care of the severely injured patient. While consultation is obtained from all necessary specialty services, the responsibility should rest with one physician who is able to evaluate the patient's overall problem. With this approach in mind, the following is a description of an approach which has proved practical and effective. <h3>Priority by Injury</h3> Patients may be placed in one of three categories, according to the severity of the injury.<sup>1</sup>The first category includes injuries which interfere with vital physiologic function and constitute an immediate threat to life, such as a gunshot wound, or an obstructed airway. The primary treatment is to establish an airway and control the bleeding. This type of patient may require surgery within five to ten minutes following arrival, especially if there is massive internal bleeding. The operating room is alerted to
Leishmaniasis Protection?
Authors: Joan Stephenson
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AB1247-HPR Interprofessional Bio-Psycho-Social Rehabilitation and Its Effects on Suffering and Occupational Performance – An Observational Study of a Cohort of 92 Chronic Pain Patients
Authors: F. Heigl, P. Schärer, C. Widmer Leu, B. Winteler, S. Bachmann, G. Caliezi, S. Reichenbach, P.M. Villiger
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Chronic musculo-skeletal diseases cause high direct and indirect costs. Chronic pain remains a challenge in clinical practice. Effectiveness of interprofessional bio-psycho-social rehabilitation programs in an outpatient setting needs to be shown<sup>1,2</sup>. <h3>Objectives</h3> To evaluate the mid- and long-term effects of an interprofessional outpatient program on the outcomes: Suffering (Self-Illness-Separation), subjective occupational performance and satisfaction, and observed occupational performance. <h3>Methods</h3> In this observational study we analyzed systematically 92 chronic pain patients (mean age =44, SD 12, with different diagnoses including non-specific low back pain and fibromyalgia). Assessments were performed pre, within (post intensive phase after 4 weeks) and post program (after 12 weeks), and after 12 months (46 patients). The intervention consists of a multimodal 12 week program (4 week intensive standard phase, followed by an 8 week individualized phase to stabilize and consolidate) including group settings (medical training, Nordic walking, psychology, leisure and ergonomics) and one to one occupational therapy including workplace visits, physiotherapy, psychology, social work, medical care, managing sleep and nutrition problems. The outcomes were evaluated with the COPM (Canadian Occupational Performance Measure), the AMPS (Assessment of Motor and Process Skills), and the PRISM (Pictural Representation of Illness and Self Measure). Descriptive statistical analysis was performed using an intention-to-treat approach with the last available data. <h3>Results</h3> All outcomes show a clinical relevant improvement in mean after 4 and 12 weeks, respectively. 1-year-follow-up shows an additional improvement in all outcomes except ADL process skills. <h3>Conclusions</h3> This 12-week multimodal bio-psycho-social outpatient rehabilitation program leads to a lasting improvement in occupational performance (subjective and observed) and reduction in suffering caused by chronic pain. The ongoing improvement over 1 year strongly suggests behavioral changes of the participants, leading to better muscular fitness and improved coping strategies. <h3>References</h3> Airaksinen O, Brox JI, Cedraschi C, Hildebrandt J, Klaber-Moffett J, Kovacs F, Mannion AF, Reis S, Staal JB, Ursin H, Zanoli G: Chapter 4: European guidelines for the management of chronic nonspecific low back pain. Eur Spine J 2006, 15(Suppl 2):S192-S300. Scottish Intercollegiate Guidelines Network (SIGN). Management of chronic pain. Edinburgh: SIGN; 2013. http://www.sign.ac.uk. <h3>Disclosure of Interest</h3> None declared
Case 39-1975
Authors: Richard C. Cabot, Robert E. Scully, James J. Galdabini, Betty U. McNeely, Richard H. Marshak, Robert E. Scully
Journal: New England Journal of Medicine (1975)

Presentation of CaseA 39-year-old man entered the hospital for evaluation of persistent epigastric pain.Sixteen years previously a diagnosis of duodenal ulcer was made because of epigastric pain and pylorospasm, with delayed emptying, demonstrated on an upper gastrointestinal examination. Episodic pain persisted, and five years later an upper gastrointestinal study (Fig. 1) showed poor coating of the duodenal bulb and narrowing of the second and third portions of the duodenum, with an effaced mucosal pattern; the jejunal mucosal folds appeared thickened. Hemigastrectomy and vagotomy were performed; the small bowel appeared normal; the pathological examination disclosed erosion of the duodenum . . .
Prolactin and cortisol responses to d-fenfluramine in major depression: evidence for diminished responsivity of central serotonergic function
Authors: V O'Keane, T G Dinan
Journal: American Journal of Psychiatry (1991)

Theoretically, d-fenfluramine should be a more selective serotonin (5-HT) challenge agent and has much greater clinical tolerance than the racemic compound that has previously been used. The authors' goal, therefore, was to look at 5-HT function in depression using the d isomer of fenfluramine as a probe.They evaluated central 5-HT function in 23 patients with DSM-III-R-diagnosed major depression and 16 healthy control subjects. The depressed group included 10 men and 13 women; four were outpatients, two attended a day hospital facility, and 17 were inpatients. Subjects were cannulated at 8:30 a.m. after an overnight fast. After baseline samples were drawn, 30 mg of d-fenfluramine was administered orally and blood samples were drawn over the following 5-hour period for prolactin and cortisol estimation.The plasma prolactin responses of the depressed patients were significantly lower than those of the control subjects. This blunting was not related to the severity of the depression but was significantly related to the patients' levels of state anxiety. Cortisol responses as well as prolactin responses were impaired in depression. High baseline cortisol levels were correlated with the severity of depression and the presence of weight loss.Overall, these findings indicate that there is diminished 5-HT responsivity in the depressed state.
Efficacy and Safety Of Three Bortezomib-Based Induction and Maintenance Regimens In Previously Untreated, Transplant-Ineligible Multiple Myeloma (MM) Patients (Pts): Final Results From The Randomized, Phase 3b, US Community-Based UPFRONT Study (NCT00507416)
Authors: Ruben Niesvizky, Ian Flinn, Robert M. Rifkin, James Essell, Yousuf Gaffar, Thomas Warr, Rachel Neuwirth, Abbie Ba-Mancini, Yanyan Zhu, Liviu Niculescu, James Reeves
Journal: Blood (2013)
NCCN Task Force Report: Prevention and Management of Mucositis in Cancer Care
Authors: William Bensinger, Mark Schubert, Kie-Kian Ang, David Brizel, Elizabeth Brown, June G. Eilers, Linda Elting, Bharat B. Mittal, Mark A. Schattner, Ricardo Spielberger, Nathaniel S. Treister, Andy M. Trotti
Journal: Journal of the National Comprehensive Cancer Network (2008)

Oral mucositis (OM) has emerged as a common cause of dose delays and interruptions of cancer therapies such as multicycle chemotherapy, myeloablative chemotherapy, and radiotherapy with or without concurrent chemotherapy of head and neck cancer. Research into both preventive and management strategies has lagged behind research into the common cancer treatment–related morbidities of nausea, vomiting, and cytopenias. This disparity is related to the complex risk assessment of multifactorial patient and treatment factors and different techniques of rating mucositis. In addition, relatively few clinical trials have focused on mucositis as a specific outcome. Currently, the only effective preventive strategies include the use of palifermin to prevent OM in the setting of hematopoietic stem cell transplantation and oral cryotherapy used in conjunction with bolus 5-FU, melphalan, or edatrexate. For the most part, managing OM relies on supportive care and symptom palliation. However, OM is a common problem associated with significant patient morbidity and increased resource use. The magnitude of the problem demands innovative approaches based on expert judgment as evidence accumulates to support specific recommendations. To improve this situation, the NCCN convened a multidisciplinary task force to address key issues. This report integrates expert judgment with a review of key literature on risk assessment, prevention, and treatment strategies, and provides recommendations for the overall management of OM. ( JNCCN 2008;6[Suppl 1]:S1–S21)
Mesothelin expression in thymic epithelial tumors (TETs).
Authors: Yuanbin Chen, Anish Thomas, Arlene W Berman, Markku Miettinen, Raffit Hassan, Arun Rajan
Journal: Journal of Clinical Oncology (2014)

7607 Background: Mesothelin (meso) is overexpressed in many solid tumors and has been used as a target for anticancer therapy. Limited data is available on meso expression in TETs and its clinical correlates. Standard treatments have limited efficacy for patients with advanced TETs, especially thymic carcinoma (TC) after failure of platinum-based chemotherapy. There is an urgent need to identify novel therapeutic targets. In view of early results demonstrating benefit in therapeutic targeting of meso, we characterized meso expression in TETs. Methods: Patients with histologically confirmed thymoma (T) or TC and available tumor tissue who were enrolled in clinical trials at the National Cancer Institute between December 2007 and December 2013 were included. Meso expression was assessed by immunohistochemistry (IHC) using monoclonal antibody 5B2 (Novocastra/Leica, Bannockburn, IL) by a pathologist who was blinded to histological subcategory (T vs. TC) and clinical outcome. IHC staining of > 50% was labeled as positive and ≤ 50% was considered negative. Associations between meso expression and patient characteristics were assessed. Results: 71 cases (42 TC; 29 T consisting of 3 WHO subtype AB, 2 B1, 13 B2 and 11 B3) were included in this series. Meso expression localized to tumor cell membrane was observed in 19 (45%) TC and 1 (3%) T. Median age and gender distribution of meso-positive vs. meso-negative TC was: 55 (21-73) vs. 50 (20-74) years and 11M/8F vs. 10M/5F respectively. Meso-expressing TC included 12 of 16 (75%) poorly differentiated carcinomas, 3 of 11 (27%) squamous cell carcinomas, 1 of 2 (50%) basaloid cancers and 0 of 8 neuroendocrine tumors (including atypical carcinoids). Median overall survival was significantly higher in meso-positive TC compared to meso-negative TC (not reached vs. 48 months; p=0.03). Extra-thoracic metastases were present in 13 of 19 (68%) meso-positive TC and 17 of 23 (74%) meso-negative TC. Conclusions: This is the largest series of meso expression in TC. Meso expression was detected in 45% of TC and associated with a significantly higher overall survival. Further studies are needed to assess the role of meso as a potential therapeutic target in TC.
Early assessment of circulating tumor cell results in a community-based practice
Authors: R. A. Beveridge, N. J. Robert, S. Desai, R. McCormack
Journal: Journal of Clinical Oncology (2005)

621 Background: Circulating tumor cells (CTC) have been shown to aid in the therapeutic management of patients with metastatic breast cancer. We chose to validate this finding, compare performance to other commonly used biological markers and determine how best to utilize this diagnostic test in community-based practice. Methods: 50 women with met breast cancer (9% first, 26% second, and 53% third or later) (27% hormonal, 64% chemo) were followed for 8 months. 72% of the patients were ER/PR positive, 71% were Her-2 negative. Pt assessment was in Fairfax, VA. and blood shipped to Veridex for analysis using CellSearch. CellSearch is an automated system with anti-EPCAM coated iron particles to capture and enrich CTC. Captured events are imaged using an automated fluorescence microscope. True epithelial cells are DAPI positive (nuclear stain), cytokeratin 8,18 or 19 positive, and CD45 negative. Results: Results were analyzed in 2 ways: for concordance of CTC and CA 27.29 to the clinical decision, and for prediction of the pt’s response to therapy at the next assessment. 26 progressions were recorded by clinical exam. 50% of the samples analyzed had 0 cells, while 23% exceeded the cutoff of 5 CTC. Of the 18 positive CellSearch tests recorded during this study, 15 (83%) were true positives (sensitivity of 58%). 21 of 44 positive CA27.29 results were true positives (48%) for a sensitivity of 88%. The low number of false positive CTC results (3) compared to the relatively high number of false positive CA 27.29 results (23), resulted in a much higher positive predictive value (PPV) of CellSearch (83%) compared to CA 27.29 (48%). In comparing results to next patient visit, the resulting sensitivity, specificity, and PPV for CellSearch increased (72%, 100%, and 100% respectively) compared to the performance of CA 27.29, which remained unchanged (86%, 36%, and 40%). Conclusions: We conclude that the overall accuracy of the CellSearch CTC test compared to the CA 27.29 test (80% v 54%, p<0.01) makes CTC counts a more reliable indicator and predictor of therapeutic failure. Our results indicate that a CellSearch result greater than 5 CTC indicates therapeutic failure with high accuracy, whereas the high false positive rate of tumor markers makes them less reliable. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Veridex Veridex
Dual pH-sensitive micelles with charge-switch for controlling cellular uptake and drug release to treat metastatic breast cancer
Authors: Shan Tang, Qingshuo Meng, Huiping Sun, Jinghan Su, Qi Yin, Zhiwen Zhang, Haijun Yu, Lingli Chen, Wangwen Gu, Yaping Li
Journal: Biomaterials (2016)